Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
What makes a good drug target?
Gashaw I, Ellinghaus P, Sommer A, Asadullah K. Gashaw I, et al. Among authors: sommer a. Drug Discov Today. 2012 Feb;17 Suppl:S24-30. doi: 10.1016/j.drudis.2011.12.008. Epub 2011 Dec 11. Drug Discov Today. 2012. PMID: 22155646
What makes a good drug target?
Gashaw I, Ellinghaus P, Sommer A, Asadullah K. Gashaw I, et al. Among authors: sommer a. Drug Discov Today. 2011 Dec;16(23-24):1037-43. doi: 10.1016/j.drudis.2011.09.007. Epub 2011 Sep 16. Drug Discov Today. 2011. PMID: 21945861 Review.
Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines.
Eschenbrenner J, Winsel S, Hammer S, Sommer A, Mittelstaedt K, Drosch M, Klar U, Sachse C, Hannus M, Seidel M, Weiss B, Merz C, Siemeister G, Hoffmann J. Eschenbrenner J, et al. Among authors: sommer a. Front Oncol. 2011 Nov 16;1:44. doi: 10.3389/fonc.2011.00044. eCollection 2011. Front Oncol. 2011. PMID: 22649765 Free PMC article.
Isogenic human mammary epithelial cell lines: novel tools for target identification and validation. Comprehensive characterization of an isogenic human mammary epithelial cell model provides evidence for epithelial-mesenchymal transition.
Ulbricht U, Sommer A, Beckmann G, Lutzenberger M, Seidel H, Kreft B, Toschi L. Ulbricht U, et al. Among authors: sommer a. Breast Cancer Res Treat. 2013 Apr;138(2):437-56. doi: 10.1007/s10549-013-2472-7. Epub 2013 Mar 13. Breast Cancer Res Treat. 2013. PMID: 23483306
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Sommer A, Kopitz C, Schatz CA, Nising CF, Mahlert C, Lerchen HG, Stelte-Ludwig B, Hammer S, Greven S, Schuhmacher J, Braun M, Zierz R, Wittemer-Rump S, Harrenga A, Dittmer F, Reetz F, Apeler H, Jautelat R, Huynh H, Ziegelbauer K, Kreft B. Sommer A, et al. Cancer Res. 2016 Nov 1;76(21):6331-6339. doi: 10.1158/0008-5472.CAN-16-0180. Epub 2016 Aug 19. Cancer Res. 2016. PMID: 27543601
Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
Lerchen HG, Wittrock S, Stelte-Ludwig B, Sommer A, Berndt S, Griebenow N, Rebstock AS, Johannes S, Cancho-Grande Y, Mahlert C, Greven S, Terjung C. Lerchen HG, et al. Among authors: sommer a. Angew Chem Int Ed Engl. 2018 Nov 12;57(46):15243-15247. doi: 10.1002/anie.201807619. Epub 2018 Oct 15. Angew Chem Int Ed Engl. 2018. PMID: 30180286
A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.
Böhnke N, Berger M, Griebenow N, Rottmann A, Erkelenz M, Hammer S, Berndt S, Günther J, Wengner AM, Stelte-Ludwig B, Mahlert C, Greven S, Dietz L, Jörißen H, Barak N, Bömer U, Hillig RC, Eberspaecher U, Weiske J, Giese A, Mumberg D, Nising CF, Weinmann H, Sommer A. Böhnke N, et al. Among authors: sommer a. Bioconjug Chem. 2022 Jun 15;33(6):1210-1221. doi: 10.1021/acs.bioconjchem.2c00178. Epub 2022 Jun 3. Bioconjug Chem. 2022. PMID: 35658441 Free PMC article.
1,111 results